Update on Selected Markers Used in Risk Assessment for Vascular Disease

Clinical Laboratory Science, Winter 2004 by Carreiro-Lewandowski, Eileen

23. Satoh K, Yoshida H, Iaizumi T, and others. Platelet-activating factor acetylhydrolase in plasma lipoproteins from patients with ischemic stroke. Stroke: 1992;23:1090-2.

24. Sudha S, Beiser A, Selhub J, and others. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Eng J Med 2002;346:476-83.

25. Schnyder G, Roffi M, Riccardo P, and others. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001:345; 1593-600.

26. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ:326;1419.

27. Lievers K, Afman L, Kluitjtmans L, and others. Polymorphisms in the transcobalamin gene: association with plasma homocysteine in healthy individuals and vascular disease patients. Clin Chem 2002;48(9):1383-9.

28. Bozzini C, Girellis D, Tinazzi R, and others. Biochemical and genetic markers of iron status and the risk of coronary artery disease: an angiography-based study. Clin Chem 2003:48(4);622-8.

29. Day S, Damon D, Lakshmi V, and others. Chronic iron administration increases vascular oxidative stress and accelerates arterial thrombosis. Circ 2003; 107:2601-6.

Eileen Carreiro-Lewandowski MS CLS(NCA) is a Professor at the University of Massachusetts Dartmouth, N Dartmouth MA.

Address for correspondence: Eileen Carreiro-Lewandowski MS CLS(NCA), University of Massachusetts Dartmouth, Department of Medical Laboratory Science, 285 Old Westport Rd, N Dartmouth, MA 02747-2300. (508) 999-8213, (508) 999-8418 (fax). ecarreiro@umassd.edu

Eileen Carreiro-Lewandowski MS CLS(NCA) is the Focus: Cardiac Markers guest editor.

Focus Continuing Education Credit: see pages 57 to 60 for learning objectives, test questions, and application form.